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ABSTRACT
Psoriasis is a chronic inflammatory skin disease
affecting about 1–3% of the general population.
Moderate-to-severe psoriasis is commonly
associated with various comorbidities,
including psoriatic arthritis (PsA) and cardio-
metabolic disorders such as obesity,
hypertension, diabetes, and metabolic
syndrome. There is increasing recognition that
systemic inflammation accompanies severe skin
disease. Abnormal innate and adaptive immune
responses in the skin are involved in
pathogenesis. The cytokine interleukin (IL)-
17A is produced by T helper 17 (Th17) cells,
neutrophils, mast cells, and T cytotoxic 17 cells.
IL-17 plays a key role in host defense against
extracellular bacteria and fungi. IL-17A acts on
keratinocytes to increase expression of
chemokines involved in recruiting myeloid
dendritic cells, Th17 cells, and neutrophils to
the lesion site. IL-17A also induces the
production of antimicrobial peptides and pro-
inflammatory cytokines that, in turn, may
amplify and sustain immune responses in the
skin. Blocking IL-17A improved psoriasis-like
pathology in experimental models, and
reduction in IL-17 signaling is part of the
mechanism of action of tumor necrosis factor-a
blockers. Three agents neutralizing IL-17 (i.e.,
secukinumab and ixekizumab) or antagonizing
its receptor (i.e., brodalumab) are currently being
tested for efficacy and safety in the treatment of
plaque psoriasis and PsA. Secukinumab is a fully
human IgG1 monoclonal antibody that
selectively binds and neutralizes IL-17A whose
efficacy in the therapy of chronic plaque
psoriasis has been demonstrated in different
phase II clinical trial. No new safety signals
have emerged so far.
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THE RATIONALE FOR TARGETING
IL-17 IN PSORIASIS
Plaque psoriasis is a chronic inflammatory skin
disease affecting 1–3% of the general
population causing a significant impairment of
quality of life, particularly if diffuse and
recalcitrant to treatments [1]. Psoriasis is
commonly associated with multiple
comorbidities including psoriatic arthritis
(PsA), inflammatory bowel diseases (Crohn’s
disease and ulcerative colitis), cardio-metabolic
disorders (such as myocardial infarction
hypertension, obesity, diabetes, dyslipidemia,
fatty liver disease, and hyperuricemia) [2–5].
The association between psoriasis and cardio-
metabolic comorbidities could be explained
considering unhealthy life habits (i.e.,
smoking, over-eating, and sedentary life), the
systemic nature of psoriasis-related
inflammation, as well as common genetic and
pathogenic pathways [5, 6]. The current
understanding of the psoriasis pathogenesis
assigns central importance to an interaction
between acquired and innate immunity [7]. At
the onset of the disease, plasmocytoid dendritic
cells are activated in the dermis and produce
tumor necrosis factor (TNF)-a and interleukin
(IL)-23, which promote the development of T
helper (Th)1 and Th17 lymphocytes which
largely infiltrate psoriatic skin [8]. Th17 cells
are a recently identified cluster of
differentiation (CD4)? helper T cell subset
which produce mainly IL-17A, IL-17F, IL-6,
and, to a lesser extent, TNF-a and IL-22, which
in turn are responsible for inflammatory
changes and epidermal hyperplasia [9].
Notably, TNF-a also synergizes with IL-17A to
induce many psoriasis-related genes in human
epidermal keratinocytes [10]. IL-17A is
produced not only by Th17 cells, but also by
neutrophils, mast cells, and T cytotoxic cells.
IL-17A promotes inflammation by several
actions including: overexpression of
antimicrobial peptides such as lipocalin2,
human b-defensin 2 and S100A proteins;
secretion of several CXCR1- or CXCR2-bearing
neutrophil chemoattractants such as CXCL1,
CXCL3, CXCL5, CXCL6, and CXCL8, leading to
neutrophil accumulation in psoriatic epidermis;
increased production of CCL20, which is
essential for the recruitment of both CCR6-
expressing dendritic cells and T cells in lesional
skin; high expression of intercellular adhesion
molecule-1 on endothelial cells, which is
essential for T-cell extravasation; dominant
role in inducing the expression of psoriasis
signature genes that are synergistically or
additively co-regulated together with TNF-a,
including IL-19, a potent inducer of epidermal
hyperplasia, IL-6 and IL-23A (IL-23p19) [11–13].
Blocking IL-17A results in amelioration of
psoriasis-like pathology in animal models [14].
Secukinumab (Novartis Pharma AG, Basel,
Switzerland) is a fully human IgG1j
monoclonal antibody (mAb) that selectively
binds and neutralizes IL-17A. Here, we report
the efficacy and safety results of phase II clinical
trials that investigated the efficacy and safety of
secukinumab in the therapy of chronic plaque
psoriasis and PsA.
The analysis in this article is based on
previously conducted studies, and does not
involve any new studies of human or animal
subjects performed by any of the authors.
Patient consent was obtained for the
publication of the Fig. 1.
SECUKINUMAB IN CHRONIC
PLAQUE PSORIASIS
Secukinumab demonstrated a favorable safety
and tolerability profile with robust clinical
activity, including improvements in psoriasis
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area and severity index (PASI) scores and
investigator global assessment scores in
patients with moderate-to-severe plaque
psoriasis. A single infusion of secukinumab
(3 mg/kg) resulted in rapid and sustained
improvement of psoriasis in a double-blind,
placebo-controlled, parallel-group, phase IIA
proof-of-concept study on 36 patients [15]. At
week 4, secukinumab was associated with an
early significant reduction from baseline in
mean PASI score compared to placebo (58% vs.
4%; P = 0.0001) [15]. Accordingly, 83% of
secukinumab patients versus 11% of placebo
patients achieved significant decreases from
baseline in investigator global assessment score
(P = 0.0004) [15]. Benefits were maintained at
week 12, with similar rates of adverse events
(AEs), including infections, in both groups [15].
Consistent with the significant decrease in skin
inflammation that was clinically evident,
molecular profiling of psoriatic skin samples
following treatment with secukinumab showed
selective modulation of cytokines, including
IL-12B, IL-17A, IL-17F, IL-21, IL-22, IL-26,
interferon (IFN)-c, and TNF-a [15]. These
molecules are expressed by leukocyte and by
tissue lineages, pointing to a diverse impact of
IL-17A on multiple cellular lineages involved in
psoriasis pathophysiology [15].
Secukinumab was further evaluated in phase
IIB subcutaneous (SC) dose-ranging and
intravenous (IV) regimen-finding studies. In
particular, a randomized, double-blind,
parallel-group, placebo-controlled, dose-
ranging study evaluated four SC doses of
secukinumab [16]. Patients (n = 125) were
randomized 1:1:1:1:1 to receive doses of
placebo (n = 22) or secukinumab [1 9 25 mg
(n = 29), 3 9 25 mg (n = 26), 3 9 75 mg
(n = 21), or 3 9 150 mg (n = 27)] at weeks 0, 4,
and 8. After the 12-week treatment, patients
entered a follow-up period of 24 weeks.
Secukinumab 150 mg and 75 mg (each
administered at weeks 0, 4, and 8) were
associated with significantly greater rates of
PASI 75 response at week 12 compared with
placebo (82% and 57% vs. 9%; P\0.001 and
P = 0.002, respectively; Table 1). Results also
Fig. 1 Diffuse erythematous plaques of the lower limbs at baseline (a) and after 12 weeks of treatment with secukinumab
150 mg subcutaneously week 0, 4, and 8 (b)
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indicated that doses of secukinumab higher
than 75 mg led to higher efficacy and higher
doses of secukinumab may be required for some
patients with greater body weight. Rates of AEs
and serious AEs (SAEs) were comparable
between secukinumab and placebo cohorts.
On the basis of the findings indicating the
safety and efficacy of secukinumab 150 mg, a
placebo-controlled phase IIB trial was conducted
to assess 3 regimens of SC secukinumab 150 mg
in patients (n = 404) with moderate-to-severe
plaque psoriasis, including single regimen (week
0; n = 67), early (weeks 0, 1, 2, 4; n = 133), and
monthly (weeks 0, 4, 8; n = 138) [17]. Early and
monthly regimens resulted in significantly
greater rates of PASI 75 response at week 12, the
primary efficacy endpoint of the study, compared
to placebo (54.5% and 42% vs. 2%; P\0.001 for
both comparisons; Table 1) [17]. The trial also
investigated maintenance treatment strategies
and secukinumab showed to offer patients and
physicians the choice of either a fixed interval
treatment regimen (every 4 weeks) or flexible
dosing [17]. However, the maintenance period
revealed a favorable efficacy profile of fixed
interval period (84.6% of patients) versus the
on-demand regimen (67.2%) in achieving PASI
75 at least once from week 20 to week 28. In this
study, an initial induction period (loading
dosage) followed by the continuous treatment
determined the optimal therapeutic regimen
using SC 150 mg secukinumab (Fig. 1).
Secukinumab was associated with a safety
profile comparable to placebo [17].
A similar phase IIB regimen-finding study
was conducted to evaluate IV secukinumab
induction regimens [18]. All secukinumab IV
induction regimens were associated with
significantly greater rates of PASI 75 and 90
responses at week 12 compared with placebo.
Although there were six SAEs in the
secukinumab treatment cohort, none were
considered by the investigators to be drug-
related. Currently, secukinumab is being tested
in several phase III clinical trials including a
study evaluating efficacy of withdrawal-and-
retreatment, a study comparing secukinumab
with etanercept, a study concerning moderate-
to-severe palmoplantar psoriasis and another
trial on PsA [19].
SECUKINUMAB IN PSORIATIC
ARTHRITIS
The efficacy and safety of secukinumab in
patients with moderate-to-severe PsA was
Table 1 PASI 75 response rate at week 12 in secukinumab phase II clinical trials







1 9 25 mg 0, 4, 8 4 29 [16]
3 9 25 mg 0, 4, 8 18 26 [16]
3 9 75 mg 0, 4, 8 57 21 [16]
3 9 150 mg 0, 4, 8 82 27 [16]
150 mg single 0 10 67 [17]
150 mg monthly 0, 4, 8 42 138 [17]
150 mg early 0, 1, 2, 3, 4 54 133 [17]
PASI psoriasis area and severity index
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investigated in a 24-week, randomized, double-
blind, placebo-controlled, phase II proof-of-
concept trial [20]. Patients (n = 42) with active
PsA were randomized (2:1) to receive two IV
secukinumab doses (10 mg/kg; n = 28) or
placebo (n = 14) 3 weeks apart. The primary
objective of the study was the proportion of
American College of Rheumatology 20
responses at week 6 for secukinumab versus
placebo. At week 6, ACR20 responses were 39%
(9/23) for secukinumab versus 23% (3/13) for
placebo (P = 0.27). In contrast, no differences
were registered for ACR 20 between
secukinumab versus placebo at week 12 and
week 24 [19]. At week 6, ‘good’ European
League Against Rheumatism response was seen
in 21.7% (5/23) secukinumab versus 9.1%
(1/11) in placebo group. Compared with
placebo at week 6, significant reductions were
observed among secukinumab patients for C
reactive protein (P = 0.039), erythrocyte
sedimentation rate (P = 0.038), Health
Assessment Questionnaire Disability Index
(P = 0.002) and Short Form Health Survey (SF-
36; P = 0.030) scores. The overall AE frequency
was similar between secukinumab and placebo.
Six SAEs were reported in four secukinumab
patients and one SAE in one placebo patient.
Clinical responses, acute-phase reactant and
quality of life improvements were greater with
secukinumab versus placebo, although the
primary endpoint was not achieved. Phase III
clinical trials investigating secukinumab in PsA
are ongoing.
SAFETY OF SECUKINUMAB
IN CHRONIC PLAQUE PSORIASIS
AND PSA
The crucial role of IL-17 in the innate immune
response, poses IL-17 as the main driver of the
host defense against extracellular bacterial
(Staphylococcus aureus, Klebsiella pneumoniae,
Streptococcus pneumoniae), parasitic (Toxoplasma
gondii) and fungal (Candida spp.) infections [21–
23]. Importantly, both IL-17A and IL-17F are
needed for muco-cutaneous immunity against
Candida albicans, but their effects are largely
redundant. Genetic deficiency in IL-17RA, in
humans, is associated with recurrent or
persistent muco-cutaneous infections caused by
C. albicans and, to a lesser extent, S. aureus [24].
In the aforementioned studies, secukinumab
was well tolerated, with an overall good safety
profile; none of the patients developed anti-
secukinumab antibodies and there were no
reports of injection-site reactions. Most of the
AEs were mild or moderate in severity,
particularly infections (Table 2) [16–18].
Vaccination against influenza is currently
recommended to patients suffering from
psoriasis [25]; previous studies have shown
that vaccination against influenza virus and
pneumococcus is safe with concomitant
treatment with biologics like adalimumab and
etanercept, and that it induces a satisfactory
humoral response, whereas other agents, like
rituximab, impaired vaccine effectiveness [26,
27]. Chioato et al. [28] have shown that
blockade of IL-17A by secukinumab does not
interfere with efficacy of influenza and
meningococcal vaccinations, as assessed by the
achievement of protective antibody levels.
OTHER IL-17A INHIBITORS
IN CHRONIC PLAQUE PSORIASIS
Targeting of the IL-17A pathway for the
treatment of psoriasis is being investigated with
high interest now and other two agents that
inhibit IL-17A are in phase III of clinical
development, i.e., ixekizumab and brodalumab.
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Ixekizumab is a humanized IgG4 mAb
neutralizing IL-17A. The safety and efficacy of
ixekizumab was evaluated in a phase II, double-
blind, placebo-controlled trial with 142 patients
affected by moderate-to-severe plaque-type
psoriasis [29]. Patients were randomized into
five groups receiving 150, 75, 25, 10 mg
ixekizumab or placebo, subcutaneously at 0, 2,
4, 8, 12, and 16 weeks [29]. The achievement of
75% reduction of PASI 75 after 12 weeks occurred
in 82.1%, 82.8%, 76.7%, 29.0%, and 7.7% of
patients, respectively. Regarding the safety
profile, the occurrence of AEs, including
nasopharyngitis, upper respiratory infection,
injection-site reaction, and headache, was
similar across all study groups, and no SAEs
were reported (Table 2). Phase III studies are
currently ongoing including a two head-to-head
trials with etanercept and adalimumab in
patients with PsA [30]. Ixekizumab is
undergoing evaluation as a treatment for
moderate-to-severe psoriasis in three phase III
studies, UNCOVER-1 (Clinicaltrials.gov #NCT01
474512), UNCOVER-2 (Clinicaltrials.gov
#NCT01597245), and UNCOVER-3
(Clinicaltrials.gov #NCT01646177). These three
studies have estimated completion dates
between February 2018 and April 2019 [31].
Brodalumab is a human mAb blocking
IL-17RA, the receptor subunit shared by
IL-17A, IL-17F, and IL-17A/F heterodimer
ligands. The antagonism of IL-17 signaling by
brodalumab was initially proven effective in
inducing clinical, histologic, and genomic
resolution of psoriasis after only 1 week of
treatment in a phase I, proof-of-concept study
enrolling 10 patients with psoriasis [32]. Further
substantiating the efficacy is a more recent phase
II, randomized, double-blind, placebo-controlled,
dose-ranging study involving 198 patients
randomly assigned to receive SC brodalumab at
the dosage of 280 mgmonthly, or 70, 140, 210 mg
or placebo at weeks 0, 1, 2, 4, 6, 8, and 10 [33]. This
12-week study assessed the efficacy ofbrodalumab
in treating psoriasis with a mean percentage
improvement of 45.0%, 85.9%, 86.3%, 76.0%
and 16.0% of PASI score using 280, 210, 140,
70 mg, or placebo, respectively (P\0.001 for all
comparison vs. placebo) [33]. Common AEs
occurred with greater frequency in the high-dose
brodalumab group; among the SAEs, two cases of
mild neutropenia (Grade III) were reported
(Table 2) [33].
CONCLUSION
Psoriasis is facing very rapid advances in the
understanding of its pathogenesis that drives a
fast expanding availability of new therapeutic
agents. Although anti-TNF-a drugs have
Table 2 The most frequent adverse events (occurring in more than 5% of patients) reported in phase II clinical trial with
different IL-17 inhibitors
Adverse event Proportion of patients reporting the adverse event (%)
Secukinumab [16, 17] Ixekizumab [29] Brodalumab [33]
Worsening of psoriasis 6.2–16.0 Not reported Not reported
Nasopharyngitis 12–22 11–14 3–16
Upper respiratory infection 4.8–10.3 4–10 5–12
Headache 3.4–9.1 3–14 Not reported
Injection-site erythema Not reported 3–10 3–10
IL-17 interleukin 17
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markedly improved the therapeutic options of
patients with autoimmune diseases, there is still
a need for new treatment options for patients
who lose response, fail to respond, or are
intolerant to their current treatment [34].
More specific treatment options, with fewer
side effects and a milder effect on the immune
system, need to be identified. As more studies
are performed, more clinical experience is
gained, and more biomarkers of clinical
response are identified, we will be able to
determine which drugs are the most suitable
for the long-term treatment of psoriasis.
Pharmacogenetics studies may also help to
tailor a more stratified therapeutic approach
[35, 36]. Experimental and clinical studies have
identified IL-17 as a ‘driver’ cytokine of psoriasis
and thus as an important therapeutic target.
Based on good tolerability of IL-17 antagonists
in phase II trials, it is expected that these agents
are likely to become major future therapeutics
for the treatment of psoriasis, although the
exact place of these drugs needs further study.
However, large-scale, phase III clinical trials are
ongoing and they will provide informative data
about the long-term efficacy and safety.
Secukinumab is now in an advanced phase of
development, but other anti-IL-17 agents have
been designed and they, too, may expand the
future therapeutic armamentarium. Still, the
physiologic impact of long-term IL-17
antagonism will need to be demonstrated in
larger and longer clinical trials and there might
be important differences in antagonizing IL-17A
versus the IL-17 receptor, which subtends
broader cytokine effects. Also, there is a need
for a better understanding of how IL-17
antagonism will impact PsA and other
comorbidities that are associated with psoriasis
and have a presumptive inflammatory etiology.
Of these, the role of IL-17 in cardiovascular
diseases holds special interest since there is
increasing recognition that IL-17 is a major risk
cytokine for atherosclerosis in model systems
and that reduced expression or blockade of IL-
17 can reduce formation of atherosclerosis
lesions [37].
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